Printed From BioPortfolio.com

FDA Grants Priority Review for Lilly’s Verzenio as Initial Treatment of Advanced Breast Cancer

15:51 EDT 12 Oct 2017 | Speciality Pharma Journal

INDIANAPOLIS, Oct. 12, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™(abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor. The NDA was based upon the positive interim results from MONARCH 3, a study of abemaciclib in combination with …

Original Article: FDA Grants Priority Review for Lilly’s Verzenio as Initial Treatment of Advanced Breast Cancer

More From BioPortfolio on "FDA Grants Priority Review for Lilly’s Verzenio as Initial Treatment of Advanced Breast Cancer"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches